SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Foresite Capital Management IV, LLC

CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887

Reported Value
$354M
Q2 2019
Positions
22
Filings on Record
30
2019–present window
Filed
Aug 13, 2019
original filing

Summary

Foresite Capital Management IV, LLC reported $354M in U.S.-listed holdings across 22 positions for Q2 2019.

The portfolio is heavily concentrated: Turning Point Therapeutics alone accounts for 21.1% of reported value.

Compared with Q1 2019, the fund opened 4 new positions and exited 0.

Portfolio Metrics

Turnover
+20.3%
vs prior filed quarter
Top-10 Concentration
+78.2%
share of reported value
Largest Position
+21.1%
Turning Point Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $278MQ1 ’19Q2 ’19: $354MQ3 ’19: $309MQ4 ’19: $232MQ1 ’20: $81MQ1 ’20Q2 ’20: $205MQ3 ’20: $443MQ4 ’20: $921MQ1 ’21: $835MQ1 ’21Q2 ’21: $740MQ3 ’21: $679MQ4 ’21: $486MQ1 ’22: $357MQ1 ’22Q2 ’22: $371MQ3 ’22: $311MQ4 ’22: $234MQ1 ’23: $193MQ1 ’23Q2 ’23: $203MQ3 ’23: $180MQ4 ’23: $198MQ1 ’24: $198MQ1 ’24Q2 ’24: $149MQ3 ’24: $153MQ4 ’24: $109MQ1 ’25: $111MQ1 ’25Q2 ’25: $124MQ3 ’25: $183MQ4 ’25: $230MQ1 ’26: $237MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 68.3%Other: 31.7%
  • Common Stock · 68.3% · $242M
  • Other · 31.7% · $112M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Turning Point Therapeutics, Inc.NEW+1.83M1.83M+$74M$74M
The Medicines CompanyNEW+249.7K249.7K+$9M$9M
NGM Biopharmaceuticals, Inc.NEW+471.3K471.3K+$7M$7M
VCYTVeracyte, Inc.NEW+200.0K200.0K+$6M$6M
Aerie Pharmaceuticals, Inc.ADDED+589.2K801.0K+$14M$24M
VYGRVoyager Therapeutics, Inc.ADDED+359.0K536.8K+$11M$15M
IMMUImmunomedics, Inc.TRIMMED−776.2K385.8K−$17M$5M
Myokardia, Inc.TRIMMED−127.5K257.5K−$7M$13M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

20 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Turning Point Therapeutics, Inc.COM21.06%$74M1.83M
2INSMInsmed Incorporatedhistory →COM11.30%$40M1.56M
3ASNDAscendis Pharma A/Shistory →SPONSORED ADR7.99%$28M245.4K
4ALECAlector, Inc.history →COM6.14%$22M1.14M
5CYTKCytokinetics Incorporatedhistory →COM NEW6.04%$21M1.90M
6Biohaven Pharmaceutical Holding Company Ltd.COM5.32%$19M429.7K
7CymaBay Therapeutics, Inc.COM5.20%$18M2.57M
8REPLReplimune Group, Inc.history →COM5.09%$18M1.23M
9OptiNose, Inc.COM5.05%$18M2.52M
10Aerie Pharmaceuticals, Inc.COM5.01%$18M600.0K
11VYGRVoyager Therapeutics, Inc.history →COM4.13%$15M536.8K
12Myokardia, Inc.COM3.65%$13M257.5K
13RYTMRhythm Pharmaceuticals, Inc.history →COM2.92%$10M469.5K
14The Medicines CompanyCOM2.57%$9M249.7K
15NGM Biopharmaceuticals, Inc.COM1.95%$7M471.3K
16VCYTVeracyte, Inc.history →COM1.61%$6M200.0K
17IMMUImmunomedics, Inc.history →COM1.51%$5M385.8K
18SIBNSI-BONE, Inc.history →COM1.18%$4M205.6K
19ABUSArbutus Biopharma CorporationCOM0.36%$1M608.2K
20Kiniksa Pharmaceuticals, Ltd.Class A Common0.24%$866,00063.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$237M8May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$230M7Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$183M6Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$124M6Aug 12, 202513F-HRchanges · EDGAR ↗
Q1 2025$111M5May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$109M4Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$153M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$149M4Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$198M5May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$198M5Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$180M7Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$203M7Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$193M8May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M8Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$311M8Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$371M8Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$357M9May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$486M9Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$679M12Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$740M13Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$835M13May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$921M13Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$443M15Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$205M12Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$81M11May 28, 2020RESTATEMENTchanges · EDGAR ↗
Q4 2019$232M14Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$309M19Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$354M22Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$278M16May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.